Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for RedHill Biopharma (RDHL) over the last 15 years, with Q2 2025 value amounting to $4.6 million.

  • RedHill Biopharma's Cash & Equivalents fell 3655.35% to $4.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $4.6 million, marking a year-over-year decrease of 3655.35%. This contributed to the annual value of $5.6 million for FY2024, which is 7211.04% down from last year.
  • Latest data reveals that RedHill Biopharma reported Cash & Equivalents of $4.6 million as of Q2 2025, which was down 3655.35% from $4.6 million recorded in Q4 2024.
  • Over the past 5 years, RedHill Biopharma's Cash & Equivalents peaked at $76.0 million during Q1 2021, and registered a low of $4.6 million during Q4 2024.
  • In the last 5 years, RedHill Biopharma's Cash & Equivalents had a median value of $21.6 million in 2021 and averaged $25.0 million.
  • As far as peak fluctuations go, RedHill Biopharma's Cash & Equivalents soared by 16176.48% in 2021, and later plummeted by 7687.8% in 2024.
  • Quarter analysis of 5 years shows RedHill Biopharma's Cash & Equivalents stood at $29.5 million in 2021, then tumbled by 32.25% to $20.0 million in 2022, then changed by 0.0% to $20.0 million in 2023, then crashed by 76.88% to $4.6 million in 2024, then changed by 0.0% to $4.6 million in 2025.
  • Its Cash & Equivalents was $4.6 million in Q2 2025, compared to $4.6 million in Q4 2024 and $7.3 million in Q2 2024.